Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study

Table 2 Mean BP and proportion of participants reaching BP goal (<130/80 mm Hg) at weeks 12 and 52/ET

Time point	Diabetes	CKD	Chronic CVD
Week 12
n	333	93	191
OM 40/AML 5/HCTZ 12.5 mg*	138.9/81.2 (17.4/9.6)	135.0/76.5 (20.6/10.9)	137.7/81.4 (15.7/10.3)
% to goal	22	40	25
Week 52/ET
n	62	29	56
OM 40/AML 5/HCTZ 12.5 mg	121.4/74.9 (14.5/8.8)	118.4/70.9 (12.6/7.9)	127.1/77.1 (18.8/12.4)
% to goal	65	79	54
n	34	13	29
OM 40/AML 5/HCTZ 25 mg	129.5/77.2 (15.6/9.9)	126.5/72.4 (22.5/10.5)	134.2/78.0 (17.0/11.6)
% to goal	38	54	35
n	40	14	20
OM 40/AML 10/HCTZ 12.5 mg	128.8/77.0 (11.6/8.5)	122.3/70.9 (15.6/8.1)	132.9/77.6 (11.1/8.5)
% to goal	50	43	20
n	197	36	86
OM 40/AML 10/HCTZ 25 mg	136.7/79.7 (15.2/9.7)	134.0/75.0 (17.7/10.3)	138.4/82.3 (16.2/10.6)
% to goal	24	31	27

BP data are mean (SD), mm Hg.
*Week 12 data are from the end of the double-blind treatment period before all participants were switched to OM 40/AML 5/HCTZ 12.5 mg at the beginning of the open-label extension period.
AML, amlodipine; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.

ISSN: 1475-2840